Related Experiment Video
Updated: Jun 22, 2026
07:09
The Sciatic Nerve Cuffing Model of Neuropathic Pain in Mice
Published on: July 16, 2014
Botulinum toxin in pain treatment
Orlando Carlos Gomes Colhado1, Marcelo Boeing, Luciano Bornia Ortega
1Doutorando em Ciências Médicas pela USP de Ribeirão Preto. esperanssoli@uol.com.br
Revista Brasileira De Anestesiologia
|June 3, 2009
Summary
Botulinum toxin type A (BTX-A) offers a well-tolerated treatment for chronic pain, reducing analgesic use. Further research is needed to confirm its efficacy and explore its full potential in pain management.
Area of Science:
- Neuroscience
- Pharmacology
- Pain Management
Background:
- Botulinum toxin (BTX), a potent neurotoxin produced by Clostridium botulinum, is available as types A and B.
- BTX targets cholinergic synapses, inhibiting acetylcholine release and selectively weakening muscles to break the spasm-pain cycle.
- Existing studies support the efficacy and safety of BTX-A for conditions like tension headaches, migraines, and chronic lumbar pain.
Purpose of the Study:
- To review the historical development of botulinum toxin.
- To elucidate the pharmacological properties of botulinum toxin.
- To examine the clinical applications of botulinum toxin in treating diverse pain origins.
Main Methods:
- Literature review of historical data.
- Analysis of pharmacological studies on botulinum toxin.
- Synthesis of clinical evidence for botulinum toxin applications in pain management.
Main Results:
- Botulinum toxin type A demonstrates good tolerability in chronic pain management, especially when pharmacotherapy causes side effects.
- BTX-A treatment can lead to reduced reliance on analgesics.
- A single dose of BTX-A provides therapeutic effects lasting 3 to 4 months.
Conclusions:
- Botulinum toxin type A is a viable and well-tolerated option for chronic pain disorders.
- Further investigation is required to fully establish BTX-A's efficacy in chronic pain and its precise mechanisms of action.
- The potential of BTX-A in integrated, multifactorial pain treatment strategies warrants exploration.
Related Concept Videos
01:26Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin
Directly acting muscle relaxants like dantrolene and botulinum toxin (BoNT) have distinct mechanisms and applications. Dantrolene, a hydantoin derivative, acts on the ryanodine receptor (RYR1) in skeletal muscle cells. RYR1 are calcium channels present at the sarcoplasmic reticulum membrane. In response to excitation, they release calcium ions from the sarcoplasmic reticulum to the cytosol. Calcium promotes actin-myosin-mediated contraction of muscles.
The binding of dantrolene to the RYR1...
The binding of dantrolene to the RYR1...
01:31Skeletal Muscle Relaxants: Therapeutic Uses
Skeletal muscle relaxants are used to relax muscle tone and alleviate painful muscle contractions. However, the choice of skeletal muscle relaxants depends on the duration of the surgical procedure in order to minimize potential side effects. Skeletal muscle relaxants like neuromuscular blocking agents [NMBAs] are commonly employed as adjuvants alongside general anesthetics in clinical settings. NMBAs are also used to maintain controlled ventilation during surgery of the larynx or pharynx as...
01:25Analgesia and Pain Management
Pain is critical to various clinical pathologies, provoking an urgent need for effective management. Pain, whether acute or chronic, is a complex neurochemical process. Its alleviation depends on the type, with nonopioid analgesics effective for mild to moderate pain, such as musculoskeletal or inflammatory pain, while neuropathic pain responds best to anticonvulsants, tricyclic antidepressants, or serotonin/norepinephrine reuptake inhibitors. For severe acute or chronic pain, opioids may be...
01:28Classification of Skeletal Muscle Relaxants
Skeletal muscle relaxants are a group of drugs that can reduce muscle stiffness and induce temporary paralysis to relieve pain. These agents can act centrally to reduce muscle tone or spasms in painful conditions such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), or spinal injuries; they are called antispasmodics or spasmolytics.
Peripherally acting skeletal muscle relaxants interfere with the neurotransmission at the neuromuscular end plate to induce paralysis during...
Peripherally acting skeletal muscle relaxants interfere with the neurotransmission at the neuromuscular end plate to induce paralysis during...
01:20Pain
Pain serves as a critical warning signal that alerts the body to potential or actual harm. When mechanical pressure on the skin is intense, such as from a sharp pinch, the sensation transitions from touch to pain. Similarly, extreme temperatures, like a hot pot handle, convert the sensation of heat into pain. Pain can also result from overstimulation of other senses, such as blinding light, loud noise, or the intense heat from habañero peppers. This ability to sense pain is essential for...
01:09Peripherally and Centrally Acting Muscle Relaxants: A Comparison
Skeletal muscle relaxants can target the central nervous system [CNS] to reduce muscle tension or act directly at the neuromuscular junction to induce temporary paralysis. These two classes of muscle relaxants are called centrally acting muscle relaxants and peripherally acting muscle relaxants. They differ in their action, mechanism, administration route, and clinical uses.
Centrally acting muscle relaxants can be further divided into spasmolytic and antispasmodic drugs. Spasmolytic drugs,...
Centrally acting muscle relaxants can be further divided into spasmolytic and antispasmodic drugs. Spasmolytic drugs,...